2.1
Belumosudil mesilate (Rezurock, Sanofi) is indicated for 'the treatment of patients aged 12 years and older with chronic graft-versus-host disease (chronic GVHD) who have received at least two prior lines of systemic therapy'.
2 Information about belumosudil
Dosage in the marketing authorisation
2.2
The dosage schedule is available in the summary of product characteristics for belumosudil.
Price
2.3
2.4
The company has a commercial arrangement. This makes belumosudil available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.